ARTICLE | Clinical News
Enbrel etanercept: Began Phase II/III testing
March 15, 1999 8:00 AM UTC
Immunex Corp. (IMNX), Seattle, Wash. Product: Enbrel etanercept Business: Cardiovascular Therapeutic category: Immune modulation Target: TNF Description: Recombinant p75 TNF receptor linked to the Fc...